Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUTENSIN vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension,Mild essential hypertension
Hypertension
1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
The terminal elimination half-life of rauwolfia alkaloids is approximately 50-100 hours, with a mean of about 72 hours. This long half-life supports once-daily dosing and leads to slow accumulation and sustained antihypertensive effect.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Extensively metabolized in the liver via deacetylation and hydrolysis; reserpine is metabolized by CYP3A4 and carboxyl esterase.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Rautensin (rauwolfia alkaloids) is primarily excreted via hepatic metabolism and biliary-fecal elimination, with less than 1% excreted unchanged in urine. Renal excretion accounts for approximately 10% of metabolites, while biliary/fecal elimination accounts for approximately 90%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Protein binding is approximately 50-60%, primarily to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Volume of distribution (Vd) is approximately 1.6 L/kg, indicating extensive tissue distribution and accumulation in adipose tissue. This high Vd contributes to the long half-life.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability is variable, estimated at approximately 50-60% due to extensive first-pass hepatic metabolism. Bioavailability is route-specific: oral only, as no parenteral formulations are clinically available.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: contraindicated due to thiazide component.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for use in children; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at lowest dose (0.5 tablet once daily); monitor for hypotension and electrolyte imbalance.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
May cause mental depression, especially in patients with history of depression,Use caution in patients with gastric ulcers (may increase gastric acid secretion),Avoid in patients undergoing electroconvulsive therapy (ECT),May cause hypotension and bradycardia,Discontinue 2 weeks before elective surgery
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to any component,Active peptic ulcer (may exacerbate),History of electroconvulsive therapy,Parkinsonism,Depression (especially with suicidal tendencies)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, tomatoes) unless advised by a doctor. Thiazide diuretics can cause potassium depletion, but reserpine may blunt this effect. Limit alcohol consumption. Maintain adequate fluid intake to prevent dehydration.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neural tube defects, cardiovascular anomalies) at high doses. Second and third trimesters: risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use during pregnancy, especially after 20 weeks gestation.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Reserpine is excreted into breast milk. M/P ratio: approximately 1:1. Potential for serious adverse effects in the nursing infant, including respiratory depression, bradycardia, and gastrointestinal disturbances. Breastfeeding is not recommended during maternal therapy with Rautensin.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Pregnancy-induced physiologic changes (increased plasma volume, renal clearance) may lower reserpine serum levels. However, due to teratogenic and neonatal risks, Rautensin is contraindicated in pregnancy. No dosing adjustments are recommended because use is not advised. Consider alternative antihypertensives with established safety profiles.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Rautensin is a combination of Rauwolfia alkaloids (e.g., reserpine) and a thiazide diuretic (e.g., bendroflumethiazide). It is rarely used today due to better-tolerated alternatives. Monitor for orthostatic hypotension, especially in elderly. Check serum potassium and uric acid regularly due to thiazide component. Reserpine can cause depression and nasal congestion; discontinue if depressive symptoms emerge. Avoid in patients with history of depression or peptic ulcer disease.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not stop abruptly as it may cause rapid rise in blood pressure.,Rise slowly from sitting or lying down to prevent dizziness.,This medication can cause drowsiness; avoid driving until you know how it affects you.,Report any signs of depression, mood changes, or unusual tiredness.,Avoid alcohol and other sedatives; they can increase dizziness and drowsiness.,If you experience nasal congestion, it may be due to the medication; consult your doctor.,Regular blood tests are needed to monitor potassium and uric acid levels.,Use effective contraception if of childbearing age; discuss with your doctor.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUTENSIN vs ALDORIL D30, answered by our medical review team.
RAUTENSIN is a Antihypertensive that works by Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUTENSIN and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUTENSIN is: 1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUTENSIN and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUTENSIN is classified as Category C. Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neur. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.